Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-10-31

Clinical Trial Update: Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating panobinostat and ruxolitinib in myelofibrosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Panobinostat (Panobinostat)
  • Ruxolitinib (ruxolitinib)

Snippet

Sponsor: John Mascarenhas | Conditions: Myelofibrosis | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-10-31